摘要
中药注射剂作为中药科技化创新制剂,在新型冠状病毒肺炎(corona virus disease 2019,COVID-19)重症患者救治中发挥着独特优势。流行病学研究发现相当数量的COVID-19重症患者合并有高血压、冠心病等心血管疾病,在治疗的同时需进行基础疾病的控制,导致中药注射剂和西药联用的药物相互作用问题日益突出。通过查阅文献,总结归纳《新型冠状病毒肺炎诊疗方案(试行第八版)》推荐的8种常用中药注射剂对细胞色素P450酶(cytochrome P450 enzyme,CYP450)的影响,并分析其与心血管病常用西药间的代谢性药物相互作用,以期为合并心血管病的COVID-19患者的临床合理用药提供参考和借鉴,更好发扬中医药抗疫优势。
Traditional Chinese medicine injection, a scientific and technological innovation of traditional Chinese medicine, plays a unique advantage in the treatment of severe patients with new corona virus pneumonia(COVID-19). Epidemiological studies have found that a considerable number of severe patients with COVID-19 have cardiovascular diseases such as hypertension and coronary heart disease, which need to be controlled during anti-virus treatment, resulting in the increasingly prevalence of drug interactions between traditional Chinese medicine injections and chemical medicines. By consulting the literatures, we summarized the effects of eight commonly used traditional Chinese medicine injections in Diagnosis and Treatment Protocol for COVID-19(Trial Version 8) on cytochrome P450 enzyme(CYP450), and analyzed their interaction with commonly used chemical medicines for cardiovascular diseases, so as to provide references for clinical rational administration and promote the advantages of traditional Chinese medicine against the epidemic disease.
作者
安会杰
邹江冰
黄雪峰
杨琰
萧伟斌
季波
袁进
AN Hui-jie;ZOU Jiang-bing;HUANG Xue-feng;YANG Yan;XIAO Wei-bin;JI Bo;YUAN Jin(General Hospital of Southern Theatre Command,Guangzhou 510010,China;Southern Medical University,Guangzhou 510515,China)
出处
《中草药》
CAS
CSCD
北大核心
2021年第7期2178-2183,共6页
Chinese Traditional and Herbal Drugs
关键词
新型冠状病毒肺炎
中药注射剂
心血管病
化学药
细胞色素P450酶
药物相互作用
COVID-19
traditional Chinese medicine injections
cardiovascular diseases
chemical medicines
cytochrome P450 enzymes
potential drug interactions
